MarketMoodz
Gossamer Bio to meet FDA after narrow miss in pivotal PAH trial; stock sinks
Gossamer Bio plans an FDA meeting after PROSERA Phase 3 topline data for seralutinib in PAH narrowly missed the prespecified efficacy threshold, sending the stock lower in early trading. Benzinga reported the topline results, but there is no official confirmation yet from Gossamer Bio or the FDA.
Key Takeaways
- PROSERA topline results narrowly missed the primary endpoint but showed activity in advanced disease and select subgroups.
- Week 24 6MWD favored seralutinib by +28.2 m vs +13.5 m with an estimated treatment effect +13.3 m (p=0.0320).
- CTD-PAH subgroup showed +37.0 m at Week 24 (n=87, p=0.0104); REVEAL 2 Lite high/intermediate-risk showed +20.0 m (n=234, p=0.0207).
- Three of four key secondary endpoints achieved p-values below 0.0125, underscoring activity in higher-risk patients.
- Enrollment in SERANATA paused to assess regional placebo response differences; CT functional respiratory imaging substudy data anticipated; FDA meeting planned to discuss path forward.
People Involved
- No specific individuals mentioned
Entities Involved
- Gossamer Bio, Inc. Biotech company developing seralutinib for PAH
- U.S. Food and Drug Administration (FDA) Regulatory agency overseeing new drug approvals
MarketMoodz Analysis
From an investor perspective, the mix of a missed primary endpoint with meaningful secondary signals creates a nuanced regulatory outlook. An FDA meeting could steer a path forward for seralutinib, potentially through a label that reflects subgroup benefit or via a confirmatory study. For a micro-cap biotech with limited near-term catalysts, the outcome of that dialogue will be a major driver of the stock’s trajectory.
Historically, PAH drug development has rewarded robust secondary signals only when supported by confirmatory data and clear regulatory pathways. The SERANATA pause to assess regional placebo differences illustrates a real-world trial-design risk in PAH registries that investors should watch. Upcoming CT functional respiratory imaging data and the March 12 earnings report will help determine whether PROSERA signals translate into a durable value proposition.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial